Hologic, Inc. (HOLX) PEG Ratio: 0.30
Is Hologic, Inc.’s PEG ratio high or low?
Hologic, Inc.'s PEG ratio of 0.30 is 85% below its 5-year average of 1.95, near the low end of its 5-year range (0.14–5.41).
The PEG ratio for Hologic, Inc. (HOLX) is 0.30. It is equal to its 12-month average by 0.00% (0.30).
HOLX PEG Ratio Chart
HOLX Average PEG Ratio Chart
HOLX Current vs Average PEG Ratio Chart
HOLX PEG Ratio Metrics
PEG RATIO
0.30
PEG RATIO AVG TTM
0.30
PEG RATIO AVG 3Y
0.22
PEG RATIO AVG 5Y
1.95
PEG RATIO AVG 10Y
1.03
PEG RATIO AVG 15Y
0.93
PEG RATIO AVG 20Y
0.70
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
+36.36%
CURRENT VS 5Y AVG
-84.62%
CURRENT VS 10Y AVG
-70.75%
CURRENT VS 15Y AVG
-67.70%
CURRENT VS 20Y AVG
-56.91%
HOLX Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 0.30 | 0.30 | 0.22 | 1.95 |
| Moderna, Inc. (MRNA) | $18.40B | N/A | 0.18 | 0.14 | 0.14 |
| Align Technology, Inc. (ALGN) | $12.56B | 51.80 | 51.80 | 26.80 | 17.90 |
| BioNTech SE (BNTX) | $21.81B | N/A | 0.23 | 0.12 | 0.12 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 8.96 | 5.67 | 4.53 | 3.90 |
| Baxter International Inc. (BAX) | $10.49B | N/A | 0.18 | 0.70 | 1.43 |
| Waters Corporation (WAT) | $23.83B | 75.62 | 75.62 | 40.78 | 27.51 |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | N/A | 0.04 | 0.51 | 2.58 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 0.18 | 0.10 | 0.17 | 0.14 |
| Veeva Systems Inc. (VEEV) | $26.73B | 1.42 | 1.47 | 5.64 | 5.88 |
Growth-Adjusted Valuation
PEG Ratio
0.30
P/E Ratio
31.7
Hologic, Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. PEG Ratio FAQ
- What is the PEG ratio for Hologic, Inc. (HOLX)?
- The PEG ratio for HOLX stock is 0.30.
- Is Hologic, Inc.'s PEG ratio high or low?
- Hologic, Inc.'s PEG ratio of 0.30 is 85% below its 5-year average of 1.95, near the low end of its 5-year range (0.14–5.41).
- What is the TTM average PEG ratio for Hologic, Inc. (HOLX)?
- The TTM average PEG ratio for HOLX stock is 0.30.
- What is the 3Y average PEG ratio for Hologic, Inc. (HOLX)?
- The 3Y average PEG ratio for HOLX stock is 0.22.
- What is the 5Y average PEG ratio for Hologic, Inc. (HOLX)?
- The 5Y average PEG ratio for HOLX stock is 1.95.
- What is the 10Y average PEG ratio for Hologic, Inc. (HOLX)?
- The 10Y average PEG ratio for HOLX stock is 1.03.
- What is the 15Y average PEG ratio for Hologic, Inc. (HOLX)?
- The 15Y average PEG ratio for HOLX stock is 0.93.
- What is the 20Y average PEG ratio for Hologic, Inc. (HOLX)?
- The 20Y average PEG ratio for HOLX stock is 0.70.
Hologic, Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2024-09-30 | 0.30 |
| 2021-09-30 | 0.14 |
| 2019-09-30 | 5.41 |
| 2018-09-30 | 0.88 |
| 2017-09-30 | 0.11 |
| 2016-09-30 | 0.22 |
| 2015-09-30 | 0.12 |
| 2012-09-30 | 0.50 |
| 2010-09-30 | 0.68 |
| 2008-09-30 | 0.04 |
| 2007-09-30 | 0.18 |
| 2005-09-30 | 0.36 |
| 2004-09-30 | 0.11 |
| 2003-09-30 | 0.07 |
| 1999-09-30 | 0.12 |
| 1997-09-30 | 0.49 |
| 1996-09-30 | 0.08 |
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini